Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Precision Cancer Diagnostic Tests Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Precision Cancer Diagnostic Tests Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Precision Cancer Diagnostic Tests Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Imaging
    • 1.4.3 Molecular
    • 1.4.4 Histology/Cytology
    • 1.4.5 Tumor Marker Immunoassays
    • 1.4.6 POC Colon Cancer Tests
  • 1.5 Market by Application
    • 1.5.1 Global Precision Cancer Diagnostic Tests Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Other
  • 1.6 Coronavirus Disease 2019 (Covid-19): Precision Cancer Diagnostic Tests Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Precision Cancer Diagnostic Tests Industry
      • 1.6.1.1 Precision Cancer Diagnostic Tests Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Precision Cancer Diagnostic Tests Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Precision Cancer Diagnostic Tests Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Precision Cancer Diagnostic Tests Market Perspective (2015-2026)
  • 2.2 Precision Cancer Diagnostic Tests Growth Trends by Regions
    • 2.2.1 Precision Cancer Diagnostic Tests Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Precision Cancer Diagnostic Tests Historic Market Share by Regions (2015-2020)
    • 2.2.3 Precision Cancer Diagnostic Tests Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Precision Cancer Diagnostic Tests Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Precision Cancer Diagnostic Tests Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Precision Cancer Diagnostic Tests Players by Market Size
    • 3.1.1 Global Top Precision Cancer Diagnostic Tests Players by Revenue (2015-2020)
    • 3.1.2 Global Precision Cancer Diagnostic Tests Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Precision Cancer Diagnostic Tests Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Precision Cancer Diagnostic Tests Market Concentration Ratio
    • 3.2.1 Global Precision Cancer Diagnostic Tests Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Precision Cancer Diagnostic Tests Revenue in 2019
  • 3.3 Precision Cancer Diagnostic Tests Key Players Head office and Area Served
  • 3.4 Key Players Precision Cancer Diagnostic Tests Product Solution and Service
  • 3.5 Date of Enter into Precision Cancer Diagnostic Tests Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Precision Cancer Diagnostic Tests Historic Market Size by Type (2015-2020)
  • 4.2 Global Precision Cancer Diagnostic Tests Forecasted Market Size by Type (2021-2026)

5 Precision Cancer Diagnostic Tests Breakdown Data by Application (2015-2026)

  • 5.1 Global Precision Cancer Diagnostic Tests Market Size by Application (2015-2020)
  • 5.2 Global Precision Cancer Diagnostic Tests Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Precision Cancer Diagnostic Tests Market Size (2015-2020)
  • 6.2 Precision Cancer Diagnostic Tests Key Players in North America (2019-2020)
  • 6.3 North America Precision Cancer Diagnostic Tests Market Size by Type (2015-2020)
  • 6.4 North America Precision Cancer Diagnostic Tests Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Precision Cancer Diagnostic Tests Market Size (2015-2020)
  • 7.2 Precision Cancer Diagnostic Tests Key Players in Europe (2019-2020)
  • 7.3 Europe Precision Cancer Diagnostic Tests Market Size by Type (2015-2020)
  • 7.4 Europe Precision Cancer Diagnostic Tests Market Size by Application (2015-2020)

8 China

  • 8.1 China Precision Cancer Diagnostic Tests Market Size (2015-2020)
  • 8.2 Precision Cancer Diagnostic Tests Key Players in China (2019-2020)
  • 8.3 China Precision Cancer Diagnostic Tests Market Size by Type (2015-2020)
  • 8.4 China Precision Cancer Diagnostic Tests Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Precision Cancer Diagnostic Tests Market Size (2015-2020)
  • 9.2 Precision Cancer Diagnostic Tests Key Players in Japan (2019-2020)
  • 9.3 Japan Precision Cancer Diagnostic Tests Market Size by Type (2015-2020)
  • 9.4 Japan Precision Cancer Diagnostic Tests Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Precision Cancer Diagnostic Tests Market Size (2015-2020)
  • 10.2 Precision Cancer Diagnostic Tests Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Precision Cancer Diagnostic Tests Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Precision Cancer Diagnostic Tests Market Size by Application (2015-2020)

11 India

  • 11.1 India Precision Cancer Diagnostic Tests Market Size (2015-2020)
  • 11.2 Precision Cancer Diagnostic Tests Key Players in India (2019-2020)
  • 11.3 India Precision Cancer Diagnostic Tests Market Size by Type (2015-2020)
  • 11.4 India Precision Cancer Diagnostic Tests Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Precision Cancer Diagnostic Tests Market Size (2015-2020)
  • 12.2 Precision Cancer Diagnostic Tests Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Precision Cancer Diagnostic Tests Market Size by Type (2015-2020)
  • 12.4 Central & South America Precision Cancer Diagnostic Tests Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Abbott Laboratories
    • 13.1.1 Abbott Laboratories Company Details
    • 13.1.2 Abbott Laboratories Business Overview and Its Total Revenue
    • 13.1.3 Abbott Laboratories Precision Cancer Diagnostic Tests Introduction
    • 13.1.4 Abbott Laboratories Revenue in Precision Cancer Diagnostic Tests Business (2015-2020))
    • 13.1.5 Abbott Laboratories Recent Development
  • 13.2 Agilent Technologies
    • 13.2.1 Agilent Technologies Company Details
    • 13.2.2 Agilent Technologies Business Overview and Its Total Revenue
    • 13.2.3 Agilent Technologies Precision Cancer Diagnostic Tests Introduction
    • 13.2.4 Agilent Technologies Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 13.2.5 Agilent Technologies Recent Development
  • 13.3 Becton Dickinson and Company
    • 13.3.1 Becton Dickinson and Company Company Details
    • 13.3.2 Becton Dickinson and Company Business Overview and Its Total Revenue
    • 13.3.3 Becton Dickinson and Company Precision Cancer Diagnostic Tests Introduction
    • 13.3.4 Becton Dickinson and Company Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 13.3.5 Becton Dickinson and Company Recent Development
  • 13.4 Bio-Rad Laboratories
    • 13.4.1 Bio-Rad Laboratories Company Details
    • 13.4.2 Bio-Rad Laboratories Business Overview and Its Total Revenue
    • 13.4.3 Bio-Rad Laboratories Precision Cancer Diagnostic Tests Introduction
    • 13.4.4 Bio-Rad Laboratories Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 13.4.5 Bio-Rad Laboratories Recent Development
  • 13.5 Biocartis N.V.
    • 13.5.1 Biocartis N.V. Company Details
    • 13.5.2 Biocartis N.V. Business Overview and Its Total Revenue
    • 13.5.3 Biocartis N.V. Precision Cancer Diagnostic Tests Introduction
    • 13.5.4 Biocartis N.V. Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 13.5.5 Biocartis N.V. Recent Development
  • 13.6 Biocept
    • 13.6.1 Biocept Company Details
    • 13.6.2 Biocept Business Overview and Its Total Revenue
    • 13.6.3 Biocept Precision Cancer Diagnostic Tests Introduction
    • 13.6.4 Biocept Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 13.6.5 Biocept Recent Development
  • 13.7 bioMerieux SA
    • 13.7.1 bioMerieux SA Company Details
    • 13.7.2 bioMerieux SA Business Overview and Its Total Revenue
    • 13.7.3 bioMerieux SA Precision Cancer Diagnostic Tests Introduction
    • 13.7.4 bioMerieux SA Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 13.7.5 bioMerieux SA Recent Development
  • 13.8 Canon Medical Systems Corporation
    • 13.8.1 Canon Medical Systems Corporation Company Details
    • 13.8.2 Canon Medical Systems Corporation Business Overview and Its Total Revenue
    • 13.8.3 Canon Medical Systems Corporation Precision Cancer Diagnostic Tests Introduction
    • 13.8.4 Canon Medical Systems Corporation Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 13.8.5 Canon Medical Systems Corporation Recent Development
  • 13.9 Cynvenio Biosystems
    • 13.9.1 Cynvenio Biosystems Company Details
    • 13.9.2 Cynvenio Biosystems Business Overview and Its Total Revenue
    • 13.9.3 Cynvenio Biosystems Precision Cancer Diagnostic Tests Introduction
    • 13.9.4 Cynvenio Biosystems Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 13.9.5 Cynvenio Biosystems Recent Development
  • 13.10 Danaher Corporation
    • 13.10.1 Danaher Corporation Company Details
    • 13.10.2 Danaher Corporation Business Overview and Its Total Revenue
    • 13.10.3 Danaher Corporation Precision Cancer Diagnostic Tests Introduction
    • 13.10.4 Danaher Corporation Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 13.10.5 Danaher Corporation Recent Development
  • 13.11 Epigenomics AG
    • 10.11.1 Epigenomics AG Company Details
    • 10.11.2 Epigenomics AG Business Overview and Its Total Revenue
    • 10.11.3 Epigenomics AG Precision Cancer Diagnostic Tests Introduction
    • 10.11.4 Epigenomics AG Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.11.5 Epigenomics AG Recent Development
  • 13.12 Exosome Diagnostics
    • 10.12.1 Exosome Diagnostics Company Details
    • 10.12.2 Exosome Diagnostics Business Overview and Its Total Revenue
    • 10.12.3 Exosome Diagnostics Precision Cancer Diagnostic Tests Introduction
    • 10.12.4 Exosome Diagnostics Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.12.5 Exosome Diagnostics Recent Development
  • 13.13 Foundation Medicine
    • 10.13.1 Foundation Medicine Company Details
    • 10.13.2 Foundation Medicine Business Overview and Its Total Revenue
    • 10.13.3 Foundation Medicine Precision Cancer Diagnostic Tests Introduction
    • 10.13.4 Foundation Medicine Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.13.5 Foundation Medicine Recent Development
  • 13.14 General Electric Company
    • 10.14.1 General Electric Company Company Details
    • 10.14.2 General Electric Company Business Overview and Its Total Revenue
    • 10.14.3 General Electric Company Precision Cancer Diagnostic Tests Introduction
    • 10.14.4 General Electric Company Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.14.5 General Electric Company Recent Development
  • 13.15 Genomic Health
    • 10.15.1 Genomic Health Company Details
    • 10.15.2 Genomic Health Business Overview and Its Total Revenue
    • 10.15.3 Genomic Health Precision Cancer Diagnostic Tests Introduction
    • 10.15.4 Genomic Health Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.15.5 Genomic Health Recent Development
  • 13.16 Hologic
    • 10.16.1 Hologic Company Details
    • 10.16.2 Hologic Business Overview and Its Total Revenue
    • 10.16.3 Hologic Precision Cancer Diagnostic Tests Introduction
    • 10.16.4 Hologic Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.16.5 Hologic Recent Development
  • 13.17 Illumina
    • 10.17.1 Illumina Company Details
    • 10.17.2 Illumina Business Overview and Its Total Revenue
    • 10.17.3 Illumina Precision Cancer Diagnostic Tests Introduction
    • 10.17.4 Illumina Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.17.5 Illumina Recent Development
  • 13.18 Menarini Silicon Biosystems SpA
    • 10.18.1 Menarini Silicon Biosystems SpA Company Details
    • 10.18.2 Menarini Silicon Biosystems SpA Business Overview and Its Total Revenue
    • 10.18.3 Menarini Silicon Biosystems SpA Precision Cancer Diagnostic Tests Introduction
    • 10.18.4 Menarini Silicon Biosystems SpA Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.18.5 Menarini Silicon Biosystems SpA Recent Development
  • 13.19 Myriad Genetics
    • 10.19.1 Myriad Genetics Company Details
    • 10.19.2 Myriad Genetics Business Overview and Its Total Revenue
    • 10.19.3 Myriad Genetics Precision Cancer Diagnostic Tests Introduction
    • 10.19.4 Myriad Genetics Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.19.5 Myriad Genetics Recent Development
  • 13.20 NanoString Technologies
    • 10.20.1 NanoString Technologies Company Details
    • 10.20.2 NanoString Technologies Business Overview and Its Total Revenue
    • 10.20.3 NanoString Technologies Precision Cancer Diagnostic Tests Introduction
    • 10.20.4 NanoString Technologies Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.20.5 NanoString Technologies Recent Development
  • 13.21 Ortho Clinical Diagnostics
    • 10.21.1 Ortho Clinical Diagnostics Company Details
    • 10.21.2 Ortho Clinical Diagnostics Business Overview and Its Total Revenue
    • 10.21.3 Ortho Clinical Diagnostics Precision Cancer Diagnostic Tests Introduction
    • 10.21.4 Ortho Clinical Diagnostics Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.21.5 Ortho Clinical Diagnostics Recent Development
  • 13.22 QIAGEN N.V.
    • 10.22.1 QIAGEN N.V. Company Details
    • 10.22.2 QIAGEN N.V. Business Overview and Its Total Revenue
    • 10.22.3 QIAGEN N.V. Precision Cancer Diagnostic Tests Introduction
    • 10.22.4 QIAGEN N.V. Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.22.5 QIAGEN N.V. Recent Development
  • 13.23 Randox Laboratories Ltd.
    • 10.23.1 Randox Laboratories Ltd. Company Details
    • 10.23.2 Randox Laboratories Ltd. Business Overview and Its Total Revenue
    • 10.23.3 Randox Laboratories Ltd. Precision Cancer Diagnostic Tests Introduction
    • 10.23.4 Randox Laboratories Ltd. Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.23.5 Randox Laboratories Ltd. Recent Development
  • 13.24 Roche Holding AG
    • 10.24.1 Roche Holding AG Company Details
    • 10.24.2 Roche Holding AG Business Overview and Its Total Revenue
    • 10.24.3 Roche Holding AG Precision Cancer Diagnostic Tests Introduction
    • 10.24.4 Roche Holding AG Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.24.5 Roche Holding AG Recent Development
  • 13.25 Royal Philips N.V.
    • 10.25.1 Royal Philips N.V. Company Details
    • 10.25.2 Royal Philips N.V. Business Overview and Its Total Revenue
    • 10.25.3 Royal Philips N.V. Precision Cancer Diagnostic Tests Introduction
    • 10.25.4 Royal Philips N.V. Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.25.5 Royal Philips N.V. Recent Development
  • 13.26 Siemens AG
    • 10.26.1 Siemens AG Company Details
    • 10.26.2 Siemens AG Business Overview and Its Total Revenue
    • 10.26.3 Siemens AG Precision Cancer Diagnostic Tests Introduction
    • 10.26.4 Siemens AG Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.26.5 Siemens AG Recent Development
  • 13.27 Thermo Fisher Scientific
    • 10.27.1 Thermo Fisher Scientific Company Details
    • 10.27.2 Thermo Fisher Scientific Business Overview and Its Total Revenue
    • 10.27.3 Thermo Fisher Scientific Precision Cancer Diagnostic Tests Introduction
    • 10.27.4 Thermo Fisher Scientific Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.27.5 Thermo Fisher Scientific Recent Development
  • 13.28 Vela Diagnostics
    • 10.28.1 Vela Diagnostics Company Details
    • 10.28.2 Vela Diagnostics Business Overview and Its Total Revenue
    • 10.28.3 Vela Diagnostics Precision Cancer Diagnostic Tests Introduction
    • 10.28.4 Vela Diagnostics Revenue in Precision Cancer Diagnostic Tests Business (2015-2020)
    • 10.28.5 Vela Diagnostics Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Precision Cancer Diagnostic Tests status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Precision Cancer Diagnostic Tests development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Abbott Laboratories
    Agilent Technologies
    Becton Dickinson and Company
    Bio-Rad Laboratories
    Biocartis N.V.
    Biocept
    bioMerieux SA
    Canon Medical Systems Corporation
    Cynvenio Biosystems
    Danaher Corporation
    Epigenomics AG
    Exosome Diagnostics
    Foundation Medicine
    General Electric Company
    Genomic Health
    Hologic
    Illumina
    Menarini Silicon Biosystems SpA
    Myriad Genetics
    NanoString Technologies
    Ortho Clinical Diagnostics
    QIAGEN N.V.
    Randox Laboratories Ltd.
    Roche Holding AG
    Royal Philips N.V.
    Siemens AG
    Thermo Fisher Scientific
    Vela Diagnostics

    Market segment by Type, the product can be split into
    Imaging
    Molecular
    Histology/Cytology
    Tumor Marker Immunoassays
    POC Colon Cancer Tests
    Market segment by Application, split into
    Hospital
    Clinic
    Other

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Precision Cancer Diagnostic Tests status, future forecast, growth opportunity, key market and key players.
    To present the Precision Cancer Diagnostic Tests development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Precision Cancer Diagnostic Tests are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now